



Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

May 9, 2019

EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2019 and recent operational highlights on Wednesday, May 15, 2019 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell's remarks.

To participate on the live call, please dial 888-220-8451 (domestic) or +1-786-789-4776 (international), and provide the conference code 7919925 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.

About Fibrocell

Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell's pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at [@Fibrocell](https://twitter.com/Fibrocell).

Trademarks

Fibrocell[®], the Fibrocell logo, and Fibrocell Science[®] are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.

Investor & Media Relations Contact:

Karen Casey
484-713-6133
kcasey@fibrocell.com



Fibrocell Science Inc.